Lamotrigina, tambi\u00e9n conocida como Lamictal, es un medicamento anticonvulsivo que fue aprobado por la FDA<\/a> for treatment of epilepsy and bipolar disorder. Lamotrigine is used alone or with other medicines to treat seizures in patients two years and older. It may also be used as maintenance treatment in patients with bipolar disorder to help delay the occurrence of mood episodes such as depression, mania, or hypomania. Stopping lamotrigine without first talking to a prescriber can lead to uncontrolled seizures, or new or worsening mental health problems. Lamotrigine has been approved and on the market for 24 years, and is available under the brand name Lamictal and as generics.<\/p>\n Lamictal was first sold in the United States in 1994 and is manufactured by GlaxoSmithKline. It is a sodium channel blocker that helps by suppressing the excitatory neurotransmitters in the central nervous system.\u00a0 Lamictal is available both as an oral tablet and in a chewable form and is metabolized by the liver.\u00a0 Between 2005 and 2015, there were more than 900,000,000 prescriptions for the drug in the United States.\u00a0\u00a0 Lamictal has been one of GlaxoSmithKline\u2019s best-selling drugs of all time and sales between March 2007 and March 2008 exceeded $2 billion.<\/p>\n <\/p>\n Adem\u00e1s de ayudar con los trastornos del estado de \u00e1nimo de los pacientes, Lamictal tambi\u00e9n fue aprobado para su uso<\/a> como f\u00e1rmaco antiepil\u00e9ptico.<\/p>\n Un art\u00edculo escrito en 2008<\/a> by Nasser et al. reviewed evidence from Lamictal trials that were unpublished, and it concludes that lamotrigine has “very limited, if any, efficacy in the treatment of acute bipolar depression”. A Documento de 2008 de Calabrese et al.<\/a> examin\u00f3 gran parte de los mismos datos y encontr\u00f3 que en cinco estudios controlados con placebo, lamotrigina no difer\u00eda significativamente del placebo en el tratamiento de la depresi\u00f3n bipolar.<\/p>\n <\/p>\n Se ha identificado una reacci\u00f3n del sistema inmunitario muy grave y potencialmente mortal como efecto secundario del uso de Lamictal. Esta reacci\u00f3n del sistema inmunitario se llama HLH (que significa linfohistiocitosis hemofagoc\u00edtica) y hace que el sistema inmunitario da\u00f1e los tejidos y \u00f3rganos del cuerpo. Esto puede causar una inflamaci\u00f3n severa en todo el cuerpo y provocar la hospitalizaci\u00f3n y la muerte, especialmente si la reacci\u00f3n no se diagnostica y trata r\u00e1pidamente. La HLH generalmente se presenta como una fiebre persistente, generalmente superior a 101 \u00b0F, y puede provocar problemas graves con las c\u00e9lulas sangu\u00edneas y los \u00f3rganos de todo el cuerpo, como el h\u00edgado, los ri\u00f1ones, el cerebro y los pulmones.<\/p>\n <\/p>\n Seg\u00fan la Administraci\u00f3n de Alimentos y Medicamentos, se puede establecer un diagn\u00f3stico de HLH si un paciente tiene al menos cinco de los siguientes ocho signos o s\u00edntomas:<\/p>\n Los pacientes o sus cuidadores deben comunicarse con sus profesionales de la salud de inmediato si experimentan alg\u00fan s\u00edntoma de HLH mientras toman lamotrigina. La HLH puede ocurrir dentro de d\u00edas o semanas despu\u00e9s de comenzar el tratamiento. Un examen f\u00edsico y an\u00e1lisis de sangre de laboratorio espec\u00edficos y otras evaluaciones se utilizan para diagnosticar HLH. Los signos y s\u00edntomas de HLH incluyen, entre otros:<\/p>\n <\/p>\n <\/p>\n El 25 de abril de 2018, el FDA emiti\u00f3 una advertencia<\/a> that Lamictal can cause this rare, but very serious reaction.\u00a0Because of the association with HLH, the FDA required the manufacturer of Lamictal to add a new warning about the risk of HLH to the prescribing information in the lamotrigine drug labels. \u00a0The FDA also issued an alert to healthcare professionals stating they should be aware that prompt recognition and early treatment is important for improving HLH outcomes and decreasing mortality. Diagnosis is often complicated because early signs and symptoms such as fever and rash are not specific. HLH may also be confused with other serious immune-related adverse reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).<\/p>\n In the 24 years since lamotrigine\u2019s 1994 approval, the FDA identified many cases worldwide of confirmed or suspected HLH associated with the medicine in children and adults. This number includes only reports submitted to FDA and found in the medical literature, so there are likely additional cases about which the FDA is unaware. The FDA determined that \u201cthere was reasonable evidence that lamotrigine was the cause of HLH\u201d in these cases based on the timing of events and the order in which they occurred. The patients in these cases required hospitalization and received drug and other medical treatments, with one patient dying.<\/p>\n <\/p>\n Lamictal ha herido a miles de personas que no ten\u00edan idea de que la droga era peligrosa. Si usted o un ser querido ha sido diagnosticado con HLH mientras tomaba Lamictal, comun\u00edquese con Napoli Shkolnik PLLC y hable con un experto. abogado litigante farmac\u00e9utico<\/a> en Nueva York. No cobramos honorarios legales por adelantado en casos de negligencia.<\/p>","protected":false},"excerpt":{"rendered":" WE ARE NO LONGER ACCEPTING LAMICTAL CASES Background Lamotrigine, also known as Lamictal, is an anti-seizure medication that was approved by the FDA for treatment of epilepsy and bipolar disorder….<\/p>","protected":false},"featured_media":0,"menu_order":137,"template":"","practiceareas_category":[743],"class_list":["post-5934","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/practiceareas\/5934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/practiceareas\/5934\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/media?parent=5934"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/practiceareas_category?post=5934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Lamictal como f\u00e1rmaco antiepil\u00e9ptico<\/h3>\n
Lamictal y HLH<\/h3>\n
Informaci\u00f3n sobre HLH<\/h2>\n
\n
\n
Datos sobre lamotrigina (Lamictal)<\/h2>\n
\n
\n
Acci\u00f3n de la FDA por la seguridad<\/h3>\n
Hable con un abogado<\/h3>\n